These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37168401)

  • 1. Free antibodies-to-infliximab are biomarker for predicting the effect of dose intensification in pediatric Crohn's disease patients with secondary loss of response.
    Kim ES; Kwon Y; Choe YH; Kim MJ
    Therap Adv Gastroenterol; 2023; 16():17562848231170948. PubMed ID: 37168401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.
    Steenholdt C; Bendtzen K; Brynskov J; Thomsen OØ; Munck LK; Christensen LA; Pedersen G; Kjeldsen J; Ainsworth MA
    J Crohns Colitis; 2015 Mar; 9(3):238-45. PubMed ID: 25576753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease.
    Choi SY; Kang B; Lee JH; Choe YH
    Gut Liver; 2017 Jan; 11(1):55-61. PubMed ID: 27609485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Infliximab Therapy in Children with Crohn's Disease Using Trough Levels Predictors.
    Ohem J; Hradsky O; Zarubova K; Copova I; Bukovska P; Prusa R; Malickova K; Bronsky J
    Dig Dis; 2018; 36(1):40-48. PubMed ID: 28817809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-infliximab antibody concentrations can guide treatment intensification in patients with Crohn's disease who lose clinical response.
    Dreesen E; Van Stappen T; Ballet V; Peeters M; Compernolle G; Tops S; Van Steen K; Van Assche G; Ferrante M; Vermeire S; Gils A
    Aliment Pharmacol Ther; 2018 Feb; 47(3):346-355. PubMed ID: 29226370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease.
    Kim JY; Lee Y; Choe BH; Kang B
    Gut Liver; 2021 Jul; 15(4):588-598. PubMed ID: 33024062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis.
    Nanda KS; Cheifetz AS; Moss AC
    Am J Gastroenterol; 2013 Jan; 108(1):40-7; quiz 48. PubMed ID: 23147525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab trough levels are associated with endoscopic healing but not with transmural healing at one year treatment with infliximab in pediatric patients with Crohn's disease.
    Choi SY; Kwon Y; Choi S; Lee SM; Choe BH; Kang B
    Front Immunol; 2023; 14():1192827. PubMed ID: 37426637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment.
    Imaeda H; Bamba S; Takahashi K; Fujimoto T; Ban H; Tsujikawa T; Sasaki M; Fujiyama Y; Andoh A
    J Gastroenterol; 2014 Apr; 49(4):674-82. PubMed ID: 23666424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease.
    Vermeire S; Noman M; Van Assche G; Baert F; D'Haens G; Rutgeerts P
    Gut; 2007 Sep; 56(9):1226-31. PubMed ID: 17229796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease.
    Oh EH; Ko DH; Seo H; Chang K; Kim GU; Song EM; Seo M; Lee HS; Hwang SW; Yang DH; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
    World J Gastroenterol; 2017 Feb; 23(8):1489-1496. PubMed ID: 28293096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn's Disease.
    Gomes LEM; da Silva FAR; Pascoal LB; Ricci RL; Nogueira G; Camargo MG; Lourdes Setsuko Ayrizono M; Fagundes JJ; Leal RF
    Clinics (Sao Paulo); 2019 Apr; 74():e824. PubMed ID: 30994711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NUDT15 intermediate metabolisers are associated with lower loss of response in paediatric Crohn's disease patients treated by combination treatment with infliximab and azathioprine.
    Kim ES; Choi S; Choi SY; Park JH; Choe BH; Lee SY; Kim MJ; Choe YH; Kang B
    Aliment Pharmacol Ther; 2022 Apr; 55(8):1008-1015. PubMed ID: 35032047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association between drug trough concentration and disease outcome before infliximab maintenance treatment in children with Crohn's disease].
    Deng X; Yu Y; Wang XQ; Li J; Xu X; Xu CD; Xiao Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Nov; 24(11):1246-1251. PubMed ID: 36398551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
    Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
    Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of Hydrocortisone Premedication Discontinuation in Patients with Inflammatory Bowel Disease on Maintenance Therapy with Infliximab: a Prospective Clinical and Pharmacological Study.
    Tran-Minh ML; Gornet JM; Maillet M; Houze P; Simon M; McLellan P; Hassid D; Vivier-Chicoteau J; Baudry C; Hammoudi N; Allez M
    J Crohns Colitis; 2021 May; 15(5):742-748. PubMed ID: 33205193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn's Disease Exhibit Similar Pharmacokinetics.
    Colman RJ; Vuijk SA; Mathôt RAA; Van Limbergen J; Jongsma MME; Schreurs MWJ; Minar P; de Ridder L; D'Haens GRAM
    Inflamm Bowel Dis; 2024 Jan; ():. PubMed ID: 38167922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial.
    Steenholdt C; Brynskov J; Thomsen OØ; Munck LK; Fallingborg J; Christensen LA; Pedersen G; Kjeldsen J; Jacobsen BA; Oxholm AS; Kjellberg J; Bendtzen K; Ainsworth MA
    Gut; 2014 Jun; 63(6):919-27. PubMed ID: 23878167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.